+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 7Years - 17Years
All Genders
ID07439042

Randomized Trial Evaluating Buspirone for Anxiety in Children and Adolescents with Autism Spectrum Disorder

Led by Massachusetts General Hospital · Updated on 2026-09-17

20

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating buspirone, an anxiety medication, to see if it is effective, safe, and tolerable for children and adolescents aged 7 to 17 years who have autism spectrum disorder and experience anxiety. This study is a phase 4, randomized controlled trial comparing buspirone to a placebo in autistic youth with moderate to severe anxiety. Participants must meet specific diagnostic criteria and be able to swallow the medication. Participants will be randomly assigned to receive either buspirone or a matching placebo for 16 weeks. The buspirone dose will be adjusted during the first 12 weeks to find a stable dose, which will then be maintained for the last 4 weeks. Standardized anxiety assessments will be done at weeks 4, 8, 12, and 16, and any side effects will be reviewed at each visit. During the study, participants will attend regular visits for dose adjustments, anxiety evaluations, and safety monitoring. Researchers will measure changes in anxiety using tools like the Pediatric Anxiety Rating Scale and Clinical Global Impression scales. The study is sponsored by Massachusetts General Hospital and aims to understand how buspirone affects anxiety symptoms in autistic youth over the 16-week treatment period.

CONDITIONS

Brief Title

Buspirone for Anxiety in Autistic Youth

Research Team

R

Robyn P. Thom, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here